Affimed GmbH
Technologiepark
Im Neuenheimer Feld 582
Heidelberg
69120
Germany
Tel: 49-6221-65307-0
Fax: 49-6221-65307-77
Website: http://www.affimed.com/
Email: info@affimed.com
134 articles with Affimed GmbH
-
Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023
3/16/2023
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it will release full year 2022 results and corporate update on Thursday, March 23, 2023.
-
Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the AACR
3/14/2023
Affimed N.V. announced that two abstracts with clinical and preclinical data on AFM13, its anti-CD30 targeting innate cell engager, have been accepted for presentation at the Annual Meeting of the American Association for Cancer Research, taking place April 14-19, 2022 in Orlando, Florida.
-
Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13
1/9/2023
Affimed N.V. announced that the U.S. Food and Drug Administration has issued a written response to the Company’s pre-IND meeting request for the AFM13 and Artiva Biotherapeutics, Inc. ’s AB-101 co-administered combination therapy in relapsed/refractory Hodgkin lymphoma and the exploratory arm evaluating the combination in r/r CD30-positive peripheral T-cell lymphoma.
-
Affimed will not seek accelerated approval for AFM13 as a monotherapy in advanced-stage relapsed/refractory peripheral T cell lymphoma.
-
Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
12/10/2022
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced topline data from its phase 2 REDIRECT study investigating AFM13 monotherapy in patients with advanced-stage r/r PTCL.
-
Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting
12/10/2022
Affimed N.V. provided a data update from the ongoing phase 1/2 study of the Company’s lead innate cell engager AFM13 precomplexed with cord blood-derived natural killer cells in patients with CD30-positive relapsed or refractory Hodgkin and Non-Hodgkin lymphomas.
-
Setting the Stage for ASH 2022
12/9/2022
At ASH 2022, established hematology leaders like AstraZeneca, Janssen and Merck will showcase new data, and new players like Vega Therapeutics will launch new programs. -
Affimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager AFM24 in Solid Tumor Patients at the 37th SITC Annual Meeting
11/7/2022
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced data updates from two phase 1/2a trials with AFM24, the company’s tetravalent, bispecific innate cell engager, in patients with solid tumors.
-
Affimed to Report Third Quarter 2022 Financial Results & Corporate Update on November 15, 2022
11/4/2022
Affimed N.V. announced that it will release third quarter 2022 results and corporate update on Tuesday, November 15, 2022.
-
Affimed to Present at the 2022 Jefferies London Healthcare Conference
11/1/2022
Affimed N.V. announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the 2022 Jefferies London Healthcare Conference on Wednesday, November 16, 2022, at 12:55 p.m. GMT / 7:55 a.m. EST / 13:55 CET.
-
Affimed Announces Two Clinical Update Presentations on its Novel Bispecific Innate Cell Engager AFM24 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
10/5/2022
Affimed N.V. announced that two abstracts with new data on the company’s novel innate cell engager AFM24 have been accepted for poster presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer.
-
Zealand Pharma and Novo Nordisk linked resources to commercialize Zegalogue for severe hypoglycemia. For that and more from a busy week across the globe, see inside.
-
Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022
9/4/2022
Affimed N.V. announced that an abstract with clinical trial results of its innate cell engager AFM24 has been accepted for a poster presentation at the Congress of the European Society for Medical Oncology from 9-13 September 2022 in Paris.
-
Affimed to Present at Upcoming Investor Conferences in September 2022
9/1/2022
Affimed N.V. announced that the Company’s management will participate in the following investor conferences during the month of September 2022.
-
Affimed Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Progress
8/11/2022
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported financial results for the second quarter ended June 30, 2022 and provided updates on preclinical, clinical and corporate progress.
-
Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022
8/4/2022
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it will release second quarter 2022 results and corporate update on Thursday, August 11, 2022.
-
Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
6/10/2022
Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented a poster at the Annual Meeting of the European Hematology Association (EHA) in Vienna, Austria.
-
Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress
6/1/2022
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported financial results for the first quarter ended March 31, 2022 and provided an update on clinical and corporate progress.
-
Affimed to Present at the 2022 Jefferies Healthcare Conference
5/26/2022
Affimed N.V. announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 1:00 p.m. Eastern Daylight Time / 19:00 Central European Time.
-
Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
5/26/2022
Affimed N.V. announced that three abstracts of clinical trial designs of its AFM24 innate cell engager have been published and will be presented at the American Society of Clinical Oncology Annual Meeting, taking place on June 3-7, 2022 in Chicago, IL.